Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$204.93 -0.6%	$199.66	$153.58 ▼ $218.66	$362.52B	0.61	5.76 million shs	9.25 million shs
BMY Bristol-Myers Squibb	$59.59 +0.1%	$58.74	$39.35 ▼ $63.33	$121.25B	0.43	12.74 million shs	8.30 million shs
PFE Pfizer	$24.73 +0.8%	$25.98	$24.31 ▼ $31.54	$140.26B	0.61	39.24 million shs	41.78 million shs
ZTS Zoetis	$163.59 +1.0%	$166.20	$144.80 ▼ $200.33	$73.25B	0.94	2.60 million shs	2.03 million shs

Unlock the Potential in Options Trading

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.56%	+1.87%	-3.00%	+14.21%	+13.40%
BMY Bristol-Myers Squibb	+0.10%	+0.70%	-0.43%	+4.93%	+12.97%
PFE Pfizer	+0.84%	-1.84%	-5.65%	-7.07%	-10.24%
ZTS Zoetis	+1.13%	+0.63%	-4.04%	+0.60%	-0.86%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.533 of 5 stars	2.5	3.0	3.3	3.9	3.5	2.5	1.3
BMY Bristol-Myers Squibb	3.8966 of 5 stars	1.2	3.0	4.2	4.0	3.5	3.3	0.0
PFE Pfizer	4.9858 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1
ZTS Zoetis	4.6144 of 5 stars	3.5	3.0	4.2	0.4	3.6	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.92	Moderate Buy	$211.45	3.18% Upside
BMY Bristol-Myers Squibb	2.33	Hold	$57.86	-2.91% Downside
PFE Pfizer	2.63	Moderate Buy	$31.92	29.09% Upside
ZTS Zoetis	3.08	Buy	$215.90	31.98% Upside

Current Analyst Ratings Breakdown

Latest PFE, BMY, ZTS, and ABBV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/17/2025	ABBV AbbVie	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/5/2025	ABBV AbbVie	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$210.00 ➝ $240.00
3/4/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$200.00 ➝ $223.00
2/27/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$200.00 ➝ $205.00
2/14/2025	ZTS Zoetis	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$242.00 ➝ $244.00
2/14/2025	ZTS Zoetis	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$243.00 ➝ $238.00
2/10/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
2/10/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$210.00 ➝ $200.00

(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.44	$15.15 per share	13.53	$1.90 per share	107.86
BMY Bristol-Myers Squibb	$48.30B	2.51	$6.29 per share	9.48	$8.08 per share	7.38
PFE Pfizer	$63.63B	2.20	$3.88 per share	6.38	$15.81 per share	1.56
ZTS Zoetis	$9.26B	7.91	$7.35 per share	22.26	$10.65 per share	15.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.40	85.39	14.66	1.62	7.59%	296.28%	12.65%	4/25/2025 (Estimated)
BMY Bristol-Myers Squibb	-$8.95B	-$4.42	N/A	9.78	2.07	-18.53%	13.93%	2.46%	4/24/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	17.54	8.16	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.47	29.91	24.24	2.78	26.86%	53.82%	18.86%	5/6/2025 (Estimated)

Latest PFE, BMY, ZTS, and ABBV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/29/2025	N/A	PFE Pfizer	$0.67	N/A	N/A	N/A	$14.43 billion	N/A
4/25/2025	N/A	ABBV AbbVie	$2.51	N/A	N/A	N/A	$12.91 billion	N/A
4/24/2025	N/A	BMY Bristol-Myers Squibb	$1.55	N/A	N/A	N/A	$10.77 billion	N/A
2/13/2025	Q4 2024	ZTS Zoetis	$1.37	$1.40	+$0.03	$1.29	$2.30 billion	$2.32 billion
2/6/2025	Q4 2024	BMY Bristol-Myers Squibb	$1.47	$1.67	+$0.20	$0.04	$11.57 billion	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion
1/31/2025	Q4 24	ABBV AbbVie	$2.98	$2.16	-$0.82	-$0.02	$14.81 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.20%	+6.04%	273.33%	53 Years
BMY Bristol-Myers Squibb	$2.48	4.16%	+6.38%	N/A	17 Years
PFE Pfizer	$1.72	6.96%	+2.50%	121.99%	16 Years
ZTS Zoetis	$2.00	1.22%	+18.66%	36.56%	14 Years

Latest PFE, BMY, ZTS, and ABBV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/6/2025	ZTS Zoetis	quarterly	$0.50	1.2%	4/21/2025	4/21/2025	6/3/2025
2/13/2025	ABBV AbbVie	quarterly	$1.64	3.4%	4/15/2025	4/15/2025	5/15/2025
3/3/2025	BMY Bristol-Myers Squibb	quarterly	$0.62	4.14%	4/4/2025	4/4/2025	5/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	17.94	0.66	0.55
BMY Bristol-Myers Squibb	2.90	1.25	1.15
PFE Pfizer	0.63	1.00	0.73
ZTS Zoetis	1.09	1.75	1.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
BMY Bristol-Myers Squibb	76.41%
PFE Pfizer	68.36%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.08%
BMY Bristol-Myers Squibb	0.09%
PFE Pfizer	0.06%
ZTS Zoetis	0.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	50,000	1.77 billion	1.76 billion	Optionable
BMY Bristol-Myers Squibb	34,300	2.03 billion	2.03 billion	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
ZTS Zoetis	14,100	447.79 million	447.08 million	Optionable

PFE, BMY, ZTS, and ABBV Headlines

Recent News About These Companies

Trexquant Investment LP Purchases New Holdings in Zoetis Inc. (NYSE:ZTS)

April 2 at 6:46 AM | marketbeat.com

Boston Family Office LLC Sells 6,365 Shares of Zoetis Inc. (NYSE:ZTS)

April 2 at 6:28 AM | marketbeat.com

Which Is a Better Investment, Jazz Pharmaceuticals plc or Zoetis Inc. Stock?

April 1 at 9:43 PM | aaii.com

Which Is a Better Investment, Corcept Therapeutics Incorporated or Zoetis Inc. Stock?

April 1 at 9:43 PM | aaii.com

2 Recession-Proof Stocks to Buy as Goldman Sachs Sounds Alarm

April 1 at 9:43 PM | moneymorning.com

HighPoint Advisor Group LLC Increases Stock Position in Zoetis Inc. (NYSE:ZTS)

April 1 at 7:19 AM | marketbeat.com

B. Metzler seel. Sohn & Co. AG Has $33.38 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

April 1 at 6:57 AM | marketbeat.com

Alliancebernstein L.P. Sells 3,579,168 Shares of Zoetis Inc. (NYSE:ZTS)

April 1 at 6:31 AM | marketbeat.com

Edmond DE Rothschild Holding S.A. Has $43.58 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

April 1 at 6:22 AM | marketbeat.com

Axiom Investors LLC DE Acquires 52,125 Shares of Zoetis Inc. (NYSE:ZTS)

April 1 at 6:11 AM | marketbeat.com

AIA Group Ltd Raises Stock Holdings in Zoetis Inc. (NYSE:ZTS)

April 1 at 6:01 AM | marketbeat.com

Wellington Management Group LLP Boosts Stake in Zoetis Inc. (NYSE:ZTS)

April 1 at 5:53 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by O Shaughnessy Asset Management LLC

April 1 at 5:43 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by California Public Employees Retirement System

April 1 at 5:24 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Clearbridge Investments LLC

March 31 at 7:20 AM | marketbeat.com

CIBC Private Wealth Group LLC Decreases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

March 31 at 6:41 AM | marketbeat.com

Martin Currie Ltd. Reduces Stock Holdings in Zoetis Inc. (NYSE:ZTS)

March 31 at 6:39 AM | marketbeat.com

Allstate Corp Invests $2.19 Million in Zoetis Inc. (NYSE:ZTS)

March 31 at 5:11 AM | marketbeat.com

DnB Asset Management AS Raises Position in Zoetis Inc. (NYSE:ZTS)

March 31 at 5:02 AM | marketbeat.com

Rep. Robert Bresnahan, Jr. Sells Zoetis Inc. (NYSE:ZTS) Stock

March 30, 2025 | marketbeat.com

State Farm Mutual Automobile Insurance Co. Sells 26,093 Shares of Zoetis Inc. (NYSE:ZTS)

March 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
By Chris Markoch | March 23, 2025
View AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
By Gabriel Osorio-Mazilli | April 1, 2025
View 2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

PFE, BMY, ZTS, and ABBV Company Descriptions

AbbVie NYSE:ABBV

$204.93 -1.34 (-0.65%)

Closing price 04/2/2025 03:58 PM Eastern

Extended Trading

$205.05 +0.12 (+0.06%)

As of 04/2/2025 08:00 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Bristol-Myers Squibb NYSE:BMY

$59.59 +0.04 (+0.07%)

Closing price 04/2/2025 03:59 PM Eastern

Extended Trading

$59.20 -0.39 (-0.65%)

As of 04/2/2025 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Pfizer NYSE:PFE

$24.73 +0.19 (+0.77%)

Closing price 04/2/2025 03:59 PM Eastern

Extended Trading

$24.47 -0.26 (-1.05%)

As of 04/2/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Zoetis NYSE:ZTS

$163.59 +1.68 (+1.04%)

Closing price 04/2/2025 03:58 PM Eastern

Extended Trading

$161.48 -2.11 (-1.29%)

As of 04/2/2025 07:59 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time